Severe Egpa – A Role For Tezepelumab?

R. Crawford,M. Sullivan,J. Azar,C. Costello,C. Freeman

DOI: https://doi.org/10.1016/j.anai.2024.08.709

2024-10-28

Abstract:Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of necrotizing vasculitis. Mepolizumab is currently the only biologic approved for the treatment of non-severe disease. We present a case of disease remission using tezepelumab, a monoclonal antibody directed against thymic stromal lymphopoietin (TSLP). Case Description A 66-year-old gentleman with past medical history of severe uncontrolled asthma, chronic rhinosinusitis with nasal polyposis, and OSA. He was evaluated for worsening respiratory complaints including wheezing, chest tightness, and cough. Review of systems was notable for recurrent rash, peripheral neuropathy, and intermittent rectal bleeding. Symptoms were fully glucocorticoid responsive. Laboratory testing was significant for a peak eosinophil count of 3100 cells/μL with negative ANCA studies. Chest imaging confirmed waxing and waning ground glass opacities in a peripheral distribution, airway thickening, and severe air trapping. Tissue biopsies were notable for eosinophilic inflammation without evidence of vasculitis ( Figure 1) . The patient met the major diagnostic criteria for EGPA with a score of 13. During the diagnostic workup, the patient was started on monthly tezepelumab, with complete and sustained resolution of his symptoms. Transbronchial cryobiopsy obtained post tezepelumab initiation was without significant eosinophilia or inflammatory change. Discussion Current treatment options for EGPA include steroids, IL-5 inhibitors, and immunomodulatory agents. Tezepelumab is a human monoclonal antibody that blocks TSLP, part of the Th2 pathway. Our patient experienced remission of severe disease with tezepelumab. Further study is needed to elucidate whether there may be a broader role for allergic pathway blockade in the treatment paradigms for EGPA.

immunology,allergy